Abbott Laboratories agreed to pay $670 million to resolve a portion of lawsuits alleging its Similac preterm infant formula caused necrotizing enterocolitis, or NEC—inflammation and tissue death in the intestinal lining. Yet approximately 1,700 lawsuits naming Abbott remain pending in federal and state courts, covering claims on behalf of 12,700 individual infants.
This settlement is a band-aid on a larger wound. A federal judge previously upheld a $495 million verdict against Abbott in a separate NEC case, establishing clear precedent for substantial judgments. With 1,700 pending cases at an average severity comparable to that judgment, the tail risk to Abbott's balance sheet is substantial and likely underestimated by sell-side consensus.
The lawsuits span a federal multidistrict litigation (MDL) in the Northern District of Illinois—which grew from 750 cases to over 775 by February 2026—plus scattered state court actions. Mead Johnson, owned by Reckitt, faces parallel litigation over its Enfamil formula. Some claims name both defendants; others single out Abbott or Mead Johnson individually. This is an industry-wide product-liability crisis, not a company-specific misstep.
Abbott maintains confidence in its products and said it will defend the remaining cases. That language is standard litigation posture. What matters for equity holders: the company is burning legal resources at scale. Each of the 12,700 individual claims requires assessment, negotiation, or trial preparation. Defense costs alone are a drag on operating margin, and the potential for additional eight-figure settlements or verdicts—should even a fraction of pending cases reach judgment—creates a contingent liability that investors should model as a material earnings headwind through 2027-2028.
For ABT shareholders, watch two catalysts closely. First, any additional settlement announcements in 2026-2027; large bulk settlements would signal Abbott's risk assessment of remaining cases and provide clarity on total exposure. Second, trial outcomes in the MDL—a string of plaintiff victories would materially increase settlement value for outstanding cases and materially increase downside EPS revisions. Third-party litigation financing for plaintiffs' counsel is ample, so these cases will move forward regardless of appellate headwinds.
Abbott's specialty nutrition division is under siege. The company's broader medical device and diagnostic franchises remain solid, but reputational damage in infant formula—a trust-intensive category—could have long-term market-share implications for Similac that extend well beyond the current litigation.
